{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:37:26Z","timestamp":1783633046966,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5459-x","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T07:02:56Z","timestamp":1553756576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome"],"prefix":"10.1186","volume":"19","author":[{"given":"Daniel M.","family":"Halperin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Beaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beilei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel H.","family":"Bhak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Narkhede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todor","family":"Totev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei S.","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen P.","family":"Neary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"issue":"2","key":"5459_CR1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s002689900020","volume":"20","author":"W Creutzfeldt","year":"1996","unstructured":"Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg. 1996;20(2):126\u201331.","journal-title":"World J Surg"},{"issue":"4","key":"5459_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525\u201334.","journal-title":"Lancet Oncol"},{"issue":"3","key":"5459_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.6004\/jnccn.2016.0029","volume":"14","author":"MH Kulke","year":"2016","unstructured":"Kulke MH. Somatostatin analogues in neuroendocrine tumors. J Natl Compr Cancer Netw. 2016;14(3):241\u20132.","journal-title":"J Natl Compr Cancer Netw"},{"key":"5459_CR4","unstructured":"US Food and Drug Administration. Sandostatin LAR Depot prescribing information. 2014. \n                    http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/sandostatin_lar.pdf\n                    \n                  . Accessed 10 July 2018."},{"key":"5459_CR5","unstructured":"US Food and Drug Administration. Somatuline Depot prescribing information. 2007. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022074s011lbl.pdf\n                    \n                  . Accessed 10 July 2018."},{"key":"5459_CR6","unstructured":"U.S. FDA approves new indication for Ipsen's Somatuline Depot (lanreotide) injection for the treatment of carcinoid syndrome. 2017. \n                    https:\/\/www.ipsen.com\/websites\/IPSENCOM-PROD\/wp-content\/uploads\/2017\/09\/16000129\/18-09-2017-Approval-Somatuline-US-carcinoid-syndrom-FINAL.pdf\n                    \n                  . Accessed 10 July 2018."},{"issue":"3","key":"5459_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","volume":"41","author":"JL Beaumont","year":"2012","unstructured":"Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461\u20136.","journal-title":"Pancreas."},{"issue":"6","key":"5459_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11136-009-9487-x","volume":"18","author":"T Haugland","year":"2009","unstructured":"Haugland T, Vatn MH, Veenstra M, Wahl AK, Natvig GK. Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Qual Life Res. 2009;18(6):719\u201326.","journal-title":"Qual Life Res"},{"key":"5459_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7525-5-18","volume":"5","author":"C Frojd","year":"2007","unstructured":"Frojd C, Larsson G, Lampic C, von Essen L. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes. 2007;5:18.","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"5459_CR10","first-page":"604","volume":"8","author":"KOL Webster","year":"1999","unstructured":"Webster KOL, Peterman A, Lent L, Cella D. The functional assessment of chronic illness therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res. 1999;8(7):604.","journal-title":"Qual Life Res"},{"issue":"4","key":"5459_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407\u201315.","journal-title":"Control Clin Trials"},{"issue":"3","key":"5459_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, et al. The functional assessment of Cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5459_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/0163278705275340","volume":"28","author":"KJ Yost","year":"2005","unstructured":"Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005;28(2):172\u201391.","journal-title":"Eval Health Prof"},{"issue":"5","key":"5459_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jclinepi.2010.11.018","volume":"64","author":"KJ Yost","year":"2011","unstructured":"Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six PROMIS-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64(5):507\u201316.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"5459_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1023\/A:1015276414526","volume":"11","author":"D Cella","year":"2002","unstructured":"Cella D, Elizabeth AH, Kelly D. Meaningful change in Cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002;11(3):207\u201321.","journal-title":"Qual Life Res"},{"issue":"3","key":"5459_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2796.1995.tb01175.x","volume":"237","author":"MB Jacobsen","year":"1995","unstructured":"Jacobsen MB, Hanssen LE. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. J Intern Med. 1995;237(3):269\u201375.","journal-title":"J Intern Med"},{"issue":"28","key":"5459_CR17","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656\u201363.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5459_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10555-015-9573-1","volume":"34","author":"P Jimenez-Fonseca","year":"2015","unstructured":"Jimenez-Fonseca P, Carmona-Bayonas A, Martin-Perez E, et al. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2015;34(3):381\u2013400.","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"5459_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","volume":"3","author":"R Arnold","year":"2005","unstructured":"Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761\u201371.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"5459_CR20","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1007\/s00520-016-3189-z","volume":"24","author":"TP Pearman","year":"2016","unstructured":"Pearman TP, Beaumont JL, Cella D, Neary MP, Yao J. Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Support Care Cancer. 2016;24(9):3695\u2013703.","journal-title":"Support Care Cancer"},{"issue":"34","key":"5459_CR21","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1200\/JCO.2012.42.5967","volume":"30","author":"E Basch","year":"2012","unstructured":"Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30(34):4249\u201355.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5459_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12955-016-0527-2","volume":"14","author":"C Martini","year":"2016","unstructured":"Martini C, Gamper EM, Wintner L, et al. Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours. Health Qual Life Outcomes. 2016;14(1):127.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"5459_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/1756283X16674660","volume":"10","author":"DL Chan","year":"2017","unstructured":"Chan DL, Segelov E, Singh S. Everolimus in the management of metastatic neuroendocrine tumours. Ther Adv Gastroenterol. 2017;10(1):132\u201341.","journal-title":"Ther Adv Gastroenterol"},{"issue":"2","key":"5459_CR24","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","volume":"17","author":"J Rubin","year":"1999","unstructured":"Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17(2):600\u20136.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5459-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5459-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5459-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:12:44Z","timestamp":1585267964000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5459-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5459"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5459-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"assertion":[{"value":"10 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All study materials were approved by the New England Independent Review Board (NEIRB#: 16\u2013168). Patients provided their written informed consent prior to responding to the survey questions.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed the final manuscript and approve the submission. Identifying images, personal details, and clinical details of patient participants are not presented, therefore consent to publish from patient participants is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Huynh, Ms. Bhak, Mr. Narkhede, Mr. Totev, and Dr. Duh are employees of Analysis Group, Inc., a consulting company that has received research funds from Novartis Pharmaceuticals Corporation. Dr. Neary and Dr. Cai are employees of Novartis Pharmaceuticals Corporation. Ms. Beaumont, Dr. Halperin and Dr. Cella have received consulting fees from Novartis Pharmaceuticals Corporation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"274"}}